212 related articles for article (PubMed ID: 28623130)
1. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
3. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
4. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
6. Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line.
Cornelissen JJ; Wognum AW; Ploemacher RE; Frassoni F; Wagemaker G; Hagemeijer A; Löwenberg B
Leukemia; 1997 Jan; 11(1):126-33. PubMed ID: 9001428
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
[TBL] [Abstract][Full Text] [Related]
8. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
Järås M; Johnels P; Hansen N; Agerstam H; Tsapogas P; Rissler M; Lassen C; Olofsson T; Bjerrum OW; Richter J; Fioretos T
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16280-5. PubMed ID: 20805474
[TBL] [Abstract][Full Text] [Related]
9. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
10. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
11. Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
Zovko A; Yektaei-Karin E; Salamon D; Nilsson A; Wallvik J; Stenke L
Oncol Rep; 2018 Aug; 40(2):902-908. PubMed ID: 29845257
[TBL] [Abstract][Full Text] [Related]
12. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
14. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
15. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
Blood; 2017 Apr; 129(17):2384-2394. PubMed ID: 28122740
[TBL] [Abstract][Full Text] [Related]
16. Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.
Yektaei-Karin E; Zovko A; Nilsson A; Näsman-Glaser B; Kanter L; Rådmark O; Wallvik J; Ekblom M; Dolinska M; Qian H; Stenke L
Leuk Lymphoma; 2017 Aug; 58(8):1903-1913. PubMed ID: 27931141
[TBL] [Abstract][Full Text] [Related]
17. Characterization of chronic myeloid leukemia stem cells.
Gerber JM; Qin L; Kowalski J; Smith BD; Griffin CA; Vala MS; Collector MI; Perkins B; Zahurak M; Matsui W; Gocke CD; Sharkis SJ; Levitsky HI; Jones RJ
Am J Hematol; 2011 Jan; 86(1):31-7. PubMed ID: 21132730
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells.
Tusa I; Cheloni G; Poteti M; Gozzini A; DeSouza NH; Shan Y; Deng X; Gray NS; Li S; Rovida E; Dello Sbarba P
Stem Cell Reports; 2018 Oct; 11(4):929-943. PubMed ID: 30245209
[TBL] [Abstract][Full Text] [Related]
19. Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia.
Tornhamre S; Stenke L; Granzelius A; Sjölinder M; Näsman-Glaser B; Roos C; Widell S; Lindgren JA
Exp Hematol; 2003 Feb; 31(2):122-30. PubMed ID: 12591277
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman JM
Leuk Lymphoma; 1993 Sep; 11(1-2):51-61. PubMed ID: 7693107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
